title: Gingival overgrowth in cyclosporine, tacrolimus, or sirolimus-based immunosuppressive regimens and the single nucleotide IL-6 (-174 G/C) gene polymorphism.
abstract: OBJECTIVE
  Interleukin-6 (IL-6) may be involved in drug-induced gingival overgrowth (GO). The present study was conducted to assess the association between IL-6 (-174 G/C) gene polymorphism and GO in renal transplant recipients under cyclosporine (CsA), tacrolimus (Tcr), or sirolimus (Sir)-based regimens.
  
  
  METHODS
  Within an eligible population, 45 unrelated subjects were selected for each CsA, Tcr, and Sir group, totaling a sample of 135 subjects. GO was visually assessed and subjects were assigned as controls (non-responders) or cases (responders) in a post hoc definition. IL-6 gene polymorphism was assessed using the polymerase chain reaction amplification and digestion. The distribution of genotypes and allele frequencies in responders and non-responders were compared using the Chi-squared test.
  
  
  RESULTS
  The number of responders was 27 (60.0%), 13 (28.9%), and 7 (15.6%) in the CsA, Tcr, and Sir groups, respectively. No differences could be observed at frequencies of -174GG, -174CG, and -174CC genotypes when comparing responders to non-responders in the CsA, Tcr, and Sir groups. Similar to genotypes, allele frequencies showed no differences between responders and non-responders in all groups.
  
  
  CONCLUSIONS
  No association between IL-6 (-174 G/C) gene polymorphism and gingival overgrowth was observed in renal transplant recipients under CsA, Tcr, or Sir-based immunosuppressive maintenance regimens.
authors.affiliation: Department of Dental Clinics, Oral Pathology and Oral Surgery, Federal University of Minas Gerais, Belo Horizonte, Brazil.
authors.forename: Luís Otávio Miranda
authors.initials: LO
authors.lastname: Cota
authors.forename: Michelle Beatriz
authors.initials: MB
authors.lastname: Viana
authors.forename: Paula Rocha
authors.initials: PR
authors.lastname: Moreira
authors.forename: Ricardo Santiago
authors.initials: RS
authors.lastname: Gomez
authors.forename: José Roberto
authors.initials: JR
authors.lastname: Cortelli
authors.forename: Sheila Cavalca
authors.initials: SC
authors.lastname: Cortelli
authors.forename: Fernando Oliveira
authors.initials: FO
authors.lastname: Costa
mesh_terms: D000328:Adult; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D016572:Cyclosporine / Q000009:adverse effects*; D003596:Cytosine; D003774:Dental Plaque Index; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D005838:Genotype; D019214:Gingival Overgrowth / Q000139:chemically induced* / Q000145:classification / Q000235:genetics; D006147:Guanine; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015850:Interleukin-6 / Q000235:genetics*; D016030:Kidney Transplantation; D008297:Male; D010512:Periodontal Index; D011110:Polymorphism, Genetic / Q000235:genetics*; D020123:Sirolimus / Q000009:adverse effects*; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D006147:Guanine; D016572:Cyclosporine; D003596:Cytosine; D020123:Sirolimus; D016559:Tacrolimus